Trial Profile
Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin) for Treatment of Brain Metastasis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Sep 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Brain metastases; Breast cancer; Solid tumours
- Focus Adverse reactions
- Acronyms REBECA
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Feb 2013 Planned end date changed from 1 Jun 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.